Significant Agreements (Tables)

12 Months Ended

Dec. 31, 2024

Neurocrine Collaborative Agreement 2023

Schedule of allocation of variable consideration

Performance Obligation	Amount
	(in thousands)
Variable Consideration
GBA1 Program	$	7,960
2023 Discovery Program 1		363
2023 Discovery Program 2		356
2023 Discovery Program 3		305
Total	$	8,984

Schedule of allocation of fixed consideration

Performance Obligation	Amount
	(in thousands)
Fixed Consideration
GBA1 Program	$	72,459
2023 Discovery Program 1		27,807
2023 Discovery Program 2		24,807
2023 Discovery Program 3		24,807
Total	$	149,880

Neurocrine Collaborative Agreement 2019

Schedule of allocation of variable consideration

Performance Obligation	Amount
	(in thousands)
Variable Consideration
VY-AADC Program	$	53,863
FA Program		19,560
2019 Discovery Program 1		4,546
2019 Discovery Program 2		4,401
Total	$	82,370

Schedule of allocation of fixed consideration

Performance Obligation	Amount
	(in thousands)
Fixed Consideration
VY-AADC Program	$	49,045
FA Program		25,647
2019 Discovery Program 1		14,443
2019 Discovery Program 2		8,247
Total	$	97,382

2023 Neurocrine Collaborative Agreement and 2019 Neurocrine Collaborative Agreement

Schedule of collaboration receivables and contract liabilities

	Balance at						Balance at
	December 31, 2023		Additions		Deductions		December 31, 2024
		(in thousands)
Related party collaboration receivables	$	3,341	$	12,269	$	(14,934)	$	676
Contract liabilities:
Deferred revenue	$	75,240	$	1,592	$	(46,435)	$	30,397